HGF and head and neck squamous cell carcinoma: Ficlatuzumab, an anti-HGF antibody, has been investigated in clinical trials for recurrent or metastatic HNSCC, particularly in patients resistant to standard therapies such as cetuximab, platinum-based chemotherapy, and anti-PD-1 inhibitors.